Cover Image

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients

Tildrakizumab is a humanized IgG1κ monoclonal antibody that selectively targets the p19 subunit of interleukin IL-23, thereby inhibiting the IL-23/IL-17 axis, which is primarily implicated in the immunopathogenesis of psoriasis. Tildrakizumab is approved for the treatment of moderate-to-severe plaqu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Elena Campione (Author), Sara Lambiase (Author), Ruslana Gaeta Shumak (Author), Marco Galluzzo (Author), Caterina Lanna (Author), Gaetana Costanza (Author), Cristiana Borselli (Author), Fabio Artosi (Author), Terenzio Cosio (Author), Lorenzo Tofani (Author), Annunziata Dattola (Author), Francesca Di Daniele (Author), Luca Bianchi (Author)
Format:	Book
Published:	MDPI AG, 2023-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Apremilast as a Potential Targeted Therapy for Metabolic Syndrome in Patients with Psoriasis: An Observational Analysis
by: Elena Campione, et al.
Published: (2024)

Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses
by: Elena Campione, et al.
Published: (2023)

Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections
by: Campione Elena, et al.
Published: (2020)

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)
by: Diego Orsini, et al.
Published: (2024)

Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
by: Matteini E, et al.
Published: (2024)

Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis
by: Dario Buononato, et al.
Published: (2022)

Retinoids in Fungal Infections: From Bench to Bedside
by: Terenzio Cosio, et al.
Published: (2021)

A Case of Pincer Nail Successfully Treated with Tazarotene 0.1% Gel
by: Laura Vollono, et al.
Published: (2020)

Usefulness of Topical Imiquimod 3.75% in Cytokeratin 7 Positive Extramammary Paget Disease of the Vulva: Towards Personalized Therapy
by: Sara Mazzilli, et al.
Published: (2021)

Experimental Pharmacological Management of Psoriasis
by: Campione E, et al.
Published: (2021)

Lichenoid Keratosis: A Clinical Trap without Secrets for Reflectance Confocal Microscopy
by: Sara Mazzilli, et al.
Published: (2020)

Effectiveness of tildrakizumab 200 mg: an Italian multicenter study
by: Annunziata Dattola, et al.
Published: (2024)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023)

Tildrakizumab in Psoriasis and Beyond
by: Aditya K. Bubna, et al.
Published: (2024)

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
by: Luigi Gargiulo, et al.
Published: (2024)

Tildrakizumab ineffective in generalized granuloma annulare
by: Eingun James Song, MD
Published: (2021)

Efficacy of a Topical Product Containing Purified Omental Lipids and Three Anti-Itching Compounds in the Treatment of Chronic Pruritus/Prurigo Nodularis in Elderly Subjects: A Prospective, Assessor-Blinded, 4-Week Trial with Transepidermal Water Loss and Optical Coherence Tomography Assessments
by: Ardigò M, et al.
Published: (2020)

Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography
by: Annunziata Dattola, et al.
Published: (2022)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
by: Annunziata Dattola, et al.
Published: (2021)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
by: Deeti J. Pithadia, et al.
Published: (2019)

The Effectiveness of a New Topical Formulation Containing GSH-C4 and Hyaluronic Acid in Seborrheic Dermatitis: Preliminary Results of an Exploratory Pilot Study
by: Campione E, et al.
Published: (2019)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
by: Potestio L, et al.
Published: (2023)

Treatment of moderate‐to‐severe plaque psoriasis with tildrakizumab in the real‐life setting
by: Alessio Gambardella, et al.
Published: (2023)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
by: Thomas Damsin
Published: (2023)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022)

Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
by: Nicoletta Bernardini, et al.
Published: (2022)

Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report
by: Leow LJ, et al.
Published: (2022)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018)

Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?
by: Eugenia Veronica Di Brizzi, et al.
Published: (2024)

Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
by: Julia-Tatjana Maul, et al.
Published: (2024)

A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice
by: Martina Burlando, et al.
Published: (2024)

Green Nail Syndrome Treated with Ozenoxacin: Two Case Reports
by: Terenzio Cosio, et al.
Published: (2023)

New insight into the pathogenesis of nail psoriasis and overview of treatment strategies
by: Ventura A, et al.
Published: (2017)

Oral Diseases During Systemic Psoriatic Drugs: A Review of the Literature and Case Series
by: Annunziata Raimondo, et al.
Published: (2024)

A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris
by: Kazuki Yatsuzuka, et al.
Published: (2023)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
by: Näslund-Koch C, et al.
Published: (2020)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
by: Fabrizio Martora, MD, et al.
Published: (2023)

Cutaneous Eruption after SARS-CoV-2 vaccine in psoriatic patient treated with methotrexate
by: Lembo Serena, et al.
Published: (2022)

Dupilumab‐associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report
by: Marco Galluzzo, et al.
Published: (2024)